- Home
- MYN vs RXST Comparison
MYN vs RXST Comparison
Compare MYN & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYN | RXST |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.8M | 307.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYN | RXST |
|---|---|---|
| Price | $9.99 | $7.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 196.8K | ★ 813.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.13 | $6.62 |
| 52 Week High | $10.26 | $27.13 |
Technical Indicators
Market Signals| Indicator | MYN | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 38.50 |
| Support Level | $9.90 | $7.08 |
| Resistance Level | $10.21 | $9.11 |
| Average True Range (ATR) | 0.07 | 0.52 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 8.33 | 26.61 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.